Nutra Pharma (OTCMKTS:NPHC) versus Harmony Biosciences (NASDAQ:HRMY) Head-To-Head Survey

Nutra Pharma (OTCMKTS:NPHC) and Harmony Biosciences (NASDAQ:HRMY) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, earnings, profitability, risk and dividends.

Analyst Recommendations

This is a summary of recent ratings and target prices for Nutra Pharma and Harmony Biosciences, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nutra Pharma	0	0	0	0	0.00
Harmony Biosciences	1	6	4	1	2.42

Harmony Biosciences has a consensus price target of $40.89, indicating a potential upside of 31.94%. Given Harmony Biosciences’ stronger consensus rating and higher possible upside, analysts plainly believe Harmony Biosciences is more favorable than Nutra Pharma.

Earnings and Valuation

This table compares Nutra Pharma and Harmony Biosciences”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nutra Pharma	$390,000.00	5.51	-$1.29 million	N/A	N/A
Harmony Biosciences	$868.45 million	2.07	$158.69 million	$2.48	12.50

Harmony Biosciences has higher revenue and earnings than Nutra Pharma.

Insider & Institutional Ownership

86.2% of Harmony Biosciences shares are held by institutional investors. 61.5% of Nutra Pharma shares are held by company insiders. Comparatively, 11.0% of Harmony Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Nutra Pharma and Harmony Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nutra Pharma	-429.26%	N/A	-106.42%
Harmony Biosciences	16.20%	17.19%	11.99%

Volatility & Risk

Nutra Pharma has a beta of 1.29, meaning that its stock price is 29% more volatile than the S&P 500. Comparatively, Harmony Biosciences has a beta of 0.97, meaning that its stock price is 3% less volatile than the S&P 500.

Summary

Harmony Biosciences beats Nutra Pharma on 10 of the 13 factors compared between the two stocks.

About Nutra Pharma

Nutra Pharma Corp., a biopharmaceutical company, acquires, licenses, and commercializes pharmaceutical products and technologies, and homeopathic and ethical drugs for the management of pain, neurological disorders, cancer, and autoimmune and infectious diseases primarily in the United States. The company offers Nyloxin and Nyloxin Extra Strength products, which are used as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps, and neuropathic pain, as well as a topical gel for treating joint pain, and pain associated with arthritis and repetitive stress; Pet Pain-Away, a homeopathic, nonnarcotic, nonaddictive, and overthecounter pain reliever to treat chronic pain in companion animals; Luxury Feet, an over-the-counter pain reliever and antiinflammatory product to treat pain or discomfort due to high heels and stilettos; Nyloxin Military Strength for treating pain to the United States Military and Veteran's Administration; and Equine Pain-Away, an over-the-counter topical pain reliever to relieve pain in horses. It is also involved in developing RPI-78M to treat neurological diseases and autoimmune diseases, including multiple sclerosis, adrenomyeloneuropathy, amyotrophic lateral sclerosis, rheumatoid arthritis, and myasthenia gravis; RPI-MN to treat viral diseases comprising human immunodeficiency virus/AIDS and herpes, as well as for general anti-viral applications; RPI-78 for pain and arthritis; and RPI-70 for pain. The company was incorporated in 2000 and is based in Plantation, Florida.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.